@article{JGO16797,
author = {Ramesh K. Ramanathan and Glen J. Weiss and Richard G. Posner and N.V. Rajeshkumar and Gayle Jameson and Meraj Aziz and Antje Hoering and Vanessa Bolejack and Anirban Maitra and Monica Fulk and Edward C. Stites and William S. Hlavacek and Zoran Gatalica and Joanne Xiu and Manuel Hidalgo and Daniel D. Von Hoff and Michael T. Barrett},
title = {A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients},
journal = {Journal of Gastrointestinal Oncology},
volume = {8},
number = {6},
year = {2017},
keywords = {},
abstract = {Background: The choice of a regimen in metastatic pancreatic cancer patients following progression on 1st line therapy is empiric and outcomes are unsatisfactory. This phase II study was performed to evaluate the efficacy of therapy selected by immunohistochemistry (IHC) in these patients following progression after one or more therapies.
Methods: Eligible patients underwent a percutaneous biopsy of a metastatic lesion and treatment selection was determined by IHC. The study required 35 evaluable patients (power of 86%) for detecting a true 1-year survival rate of >20%.
Results: A tumor biopsy was performed in 48 of 49 accrued patients. Study therapy was not given (n=13) either due to insufficient tumor on biopsy (n=8) or due to worsening cancer related symptoms after biopsy (n=5). The demographics of evaluable patients (n=35) are male/female (59%/41%), with age range 34–78 years (median 63 years). Patients had 1–6 prior regimens (median of 2). The most common IHC targets were topoisomerase 1 or 2, thymidylate synthase, excision repair cross-complementation group 1 protein (ERCC1), and osteonectin secreted protein acidic and rich in cysteine (SPARC). Commercially available treatment regimens prescribed included FOLFIRI, FOLFOX, irinotecan, and doxorubicin. The response (RECIST) was 9%, the median survival was 5.6 months (94% CI, 3.8–8.2), and the 1-year survival was 20% (95% CI, 7–33%).
Conclusions: In all patients, IHC assays resulted in identification of at least two targets for therapy and a non-cross resistant regimen could be prescribed for therapy with evidence of some benefit. An IHC based treatment strategy is feasible and needs validation in larger studies.},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/16797}
}